New Jersey S 2143: Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.

Status: Introduced in the Senate, Referred to Senate Commerce Committee (as of 2022-03-07)

State: New Jersey · Session: 220 · Bill: S 2143

Subjects: HEALTH INSUR, PHARMACEUTIC

Sponsors: Madden, Fred H.

View New Jersey S 2143 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.